Rapport Therapeutics, Inc
Price
FilingsNewest: Form 10-Q, quarterly reportNov 4 →Insiders7 insiders bought $22.0M in 11 open-market buys. 10 insiders sold $46.7M, 63 of 66 sales on a 10b5-1 plan.→HoldersFMR 14.9%TRV GP V 13.1%ARCH Venture 7.8%→Financing →PeersClosest companies: SEPN, MBX, NEUP→
From the filings
Figures
- Net income
- −$150.5Mlast 12 months
- Operating cash flow
- −$96.7Mlast 12 months
- Cash and equivalents
- $74.8Mat the last balance sheet
- Shares outstanding
- 48.1M shareson issue
Filings, newest first
- Nov 410-QQuarterly report
- Nov 48-KResults of operations
- Nov 34Insider trade
- Oct 304Insider trade
- Oct 308-KMaterial agreement
- Oct 30424B5Offering prospectus
- Oct 30424B5Offering prospectus
- Oct 27424B5Offering prospectus
- Oct 27424B5Offering prospectus
- Oct 208-KRegulation FD disclosure
- Mar 1010-KAnnual report